Drug Company Touts Anti-Inflammatory Drug’s Role In Shortening COVID Recovery
Eli Lilly said it planned to discuss with regulators the possible emergency use of baricitinib for hospitalized patients. Other news is about early research on an antibody that might neutralize COVID and how the virus controls the brain, as well.
AP:
Anti-Inflammatory Drug May Shorten COVID-19 Recovery Time
A drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day. Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The study tested baricitinib, a pill that Indianapolis-based Lilly already sells as Olumiant to treat rheumatoid arthritis. (Marchione, 9/14)
The Hill:
Drugmaker Says Anti-Inflamatory Medicine May Shorten COVID-19 Recovery Time
The use of Baricitinib, a rheumatoid arthritis drug from Eli Lilly, led to a one-day reduction in recovery time for patients when combined with Remdesivir compared to patients who only took Remdesivir, according to a trial. The finding was statistically significant, Eli Lilly said in a statement. The company did not release the full results of the study but stated the National Institute of Allergy and Infectious Diseases (NIAID) is expected to publish full results in peer-review studies and that additional analyses are ongoing to understand clinical outcome data, including safety and morbidity data. (9/14)
In other scientific developments —
Fox News:
University Of Pittsburgh Scientists Discover Antibody That 'neutralizes' Virus That Causes Coronavirus
Scientists at the University of Pittsburgh School of Medicine have isolated “the smallest biological molecule” that “completely and specifically neutralizes” SARS-CoV-2, the virus that causes the novel coronavirus. The antibody component is 10 times smaller than a full-sized antibody, and has been used to create the drug Ab8, shared in the report published by the researchers in the journal Cell on Monday. The drug is seen as a potential preventative against SARS-CoV-2. (Deabler, 9/14)
Fox News:
Coronavirus Can 'Hijack' Brain Cells To Replicate Itself, Yale Researchers Discover
The coronavirus can affect the brain and “hijack” brain cells to replicate itself, Yale University researchers have discovered. A new study from Yale University, on BioRXiv, which is awaiting peer review, found that the brain is another organ susceptible to an attack by the novel coronavirus. (McGorry, 9/14)
Stat:
23andMe Research Finds Possible Link Between Blood Type And Covid-19
A forthcoming study from genetic testing giant 23andMe shows that a person’s genetic code could be connected to how likely they are to catch Covid-19 — and how severely they could experience the disease if they catch it. It’s an important confirmation of earlier work on the subject. People whose blood group is O seemed to test positive for Covid-19 less often than expected when compared to people with any other blood group, according to 23andMe’s data; people who tested positive and had a specific variant of another gene also seemed to be more likely to have serious respiratory symptoms. (Sheridan, 9/14)
